Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 3 2Phase 4 1Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Follicular 6Lymphoma 6Myelodysplastic Syndromes 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myeloid, Acute 5Leukemia 5Neoplasms, Plasma Cell 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, B-Cell, Marginal Zone 4Hodgkin Disease 4Dendritic Cell Sarcoma, Interdigitating 4Burkitt Lymphoma 4Thrombocythemia, Essential 3Recurrence 3Primary Myelofibrosis 3Myeloproliferative Disorders 3Lymphoma, T-Cell, Cutaneous 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Lymphocytic, Chronic, B-Cell 3Graft vs Host Disease 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Polycythemia Vera 2Mycosis Fungoides 2

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Methylprednisolone × Clear all
NCT05280873 2022-03-15

Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP

Guangzhou Institute of Respiratory Disease

Phase 1 Unknown
48 enrolled

Neoplasms, Pneumonia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡